ABSTRACT

Introduction: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, an autoimmune disorder resulting from antibodies directed against the NMDA (glutamate) receptor, is the second most frequent cause of immune-mediated encephalitis. To date, the information related to the anesthetic care of children with this disorder is limited to anecdotal reports.

Methods: We reviewed the anesthetic care of six patients with anti-NMDA receptor encephalitis who underwent 21 procedures at our institution from 2014 through 2019.

Results: The study cohort included six patients, ranging in age from 2 to 18 years, who required anesthetic care during 21 procedures. Airway management included a laryngeal mask airway (n = 8), endotracheal intubation (n = 12), and native airway with spontaneous ventilation (n = 1). Intravenous (IV) induction with propofol was used in 17 procedures for five patients, including three that required rapid sequence intubation using rocuronium or succinylcholine. Inhalation induction with sevoflurane in nitrous oxide (N₂O)/oxygen (O₂) was chosen for two procedures in two patients. A combination of both induction techniques was used for two patients in two procedures. Maintenance anesthesia was accomplished with a volatile agent, predominantly sevoflurane, for 18 of the 21 procedures; propofol infusion for one procedure; and single dose of propofol was used for two short procedures. N₂O was not used for maintenance anesthesia in any of the encounters. None of the patients exhibited adverse events, including hemodynamic instability, thermoregulatory problems, or respiratory events perioperatively. Postoperatively, there was no observed deterioration in clinical status attributed to anesthetic care.

Discussion: Multisystem involvement in anti-NMDA receptor encephalitis includes memory loss, behavior irregularity, psychosis, arrhythmias, blood pressure (BP) instability, and hypoventilation. In our study cohort, we noted no intraoperative issues and deterioration in clinical status following the use of volatile anesthetic agents, opioids, dexmedetomidine, and propofol for general anesthesia (GA) or sedation. As ketamine, xenon, and N₂O mediate their anesthetic effects, primarily, through antagonism of NMDA receptors, theoretical concerns suggest that they should be avoided.

Key words: Anti-NMDA receptor encephalitis; autoimmune; encephalitis; NMDA receptor

Access this article online

Website: www.saudija.org

DOI: 10.4103/sja.SJA_720_19

How to cite this article: Al Ghamdi F, Uffman JC, Kim SS, Nafiu OO, Tobias JD. Anesthetic care for patients with anti-NMDA receptor encephalitis. Saudi J Anaesth 2020;14:164-8.

Faris Al Ghamdi¹, Joshua C. Uffman¹,², Stephani S. Kim¹, Olubukola O. Nafiu¹,², Joseph D. Tobias¹,²,³

¹Department of Anesthesiology and Pain Medicine, Nationwide Children’s Hospital, Columbus, Ohio, ²Department of Anesthesiology and Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ³Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA

Address for correspondence: Dr. Joseph D. Tobias, Department of Anesthesiology and Pain Medicine, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, Ohio 43205, USA. E-mail: Joseph.Tobias@NationwideChildrens.org

Submitted: 14-Nov-2019, Accepted: 15-Nov-2019, Published: 05-Mar-2020
Introduction

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disorder resulting from antibodies directed against the NMDA (glutamate) receptor. First reported in 2005 in a series of four women with ovarian teratomas, it is now recognized as the second most frequent cause of immune-mediated encephalitis.\(^\text{[1,2]}\) The disorder has been most commonly reported in young African American women between 18 and 35 years of age.\(^\text{[3]}\) However, cases in infants and the elderly have also been reported.\(^\text{[3,5]}\) Clinical features include an initial presentation with psychosis, memory deficits, seizures, and language disintegration, which progresses to impaired consciousness, coma, and respiratory insufficiency.\(^\text{[6,7]}\) Cardiovascular manifestations include arrhythmias, bradycardia progressing to cardiac arrest, hypotension, and autonomic instability. Prior to the characterization of the autoimmune nature of this disorder and its clinical features, patients were frequently erroneously diagnosed with schizophrenia and other mental health issues. The clinical symptomatology, cerebrospinal fluid (CSF) lymphocytosis, and an abnormal electroencephalogram (EEG) suggest the diagnosis with delta or theta activity. The diagnosis is confirmed by the presence of antibodies in the CSF against the NMDA receptor.\(^\text{[6,7]}\)

Given its predominant neurologic presentation and the association with abdominal tumors (teratomas), patients with anti-NMDA receptor encephalitis often present for surgical or radiologic procedures that require anesthetic care. To date, there is limited evidence-based medicine regarding the anesthetic care of such patients, with information restricted to anecdotal reports including 1–2 patients.\(^\text{[9‑13]}\) The current report retrospectively reviews the anesthetic management of the largest series of pediatric cases of anti-NMDA receptor encephalitis.

Methods

This retrospective review was approved by the Institutional Review Board of Nationwide Children’s Hospital (Columbus, Ohio). Patients with a diagnosis of anti-NMDA receptor encephalitis confirmed by clinical features of the disease and the presence of positive blood and CSF NMDA receptor antibody assays between 2014 and 2019 were identified from our electronic database. Patients who subsequently received anesthetic or procedural sedation care were included in the study cohort. Data retrieved included the patient demographic data; clinical presentation; type of procedure (radiological or surgical); and anesthetic management, including anesthetic agents used, type of induction, airway management technique, postoperative complications, and postanesthesia care unit (PACU) time. Specific postoperative complications included postoperative respiratory adverse events (PRAEs), including bronchospasm, laryngospasm, apnea/hypopnea, or hypoxemia/prolonged oxygen (O\(_2\)) requirement. The clinical significance of the event was then confirmed by the need for intervention or pharmacologic treatment. Bronchospasm was considered significant if treated with a bronchodilatory agent (albuterol, inhaled racemic epinephrine, intravenous (IV) epinephrine, ketamine). Laryngospasm was confirmed by the need for the application of positive pressure for O\(_2\) saturation (SpO\(_2\)) <90% or the administration of propofol or succinylcholine. Apnea or hypopnea was defined as the need for bag-valve-mask ventilation. Hypoxemia/prolonged O\(_2\) requirement was defined as the need for supplemental O\(_2\) for >90 min to maintain O\(_2\) saturation >90%. Hemodynamic adverse events were described as a heart rate less than the fifth percentile for age for bradycardia and systolic blood pressure (SBP) less than fifth percentile for age for hypotension. These events were judged clinically significant if the treatment with an anticholinergic agent, vasoactive agent, or fluid was administered.

Demographic data are presented as the mean ± standard deviation (SD). Categorical variables are summarized as counts with percentages. Continuous variables are summarized as medians with interquartile ranges (IQRs) and compared using rank sum tests.

Results

The study cohort included 6 patients (2 male and 4 female)—in 2 to 18 years age range and weighing between 11.6 and 77.2 kg—who required anesthetic care during 21 imaging, invasive, or surgical procedures [Table 1]. In all the cases, the patients’ initial clinical presentation consisted of the sudden onset of psychobehavioral abnormalities, agitation, memory deficits, language disintegration, movement disorders, and/or seizures. Due to a decreased level of conciseness, one of the six patients required intensive care unit (ICU) admission, endotracheal intubation, and mechanical ventilation.

Table 1: Demographic data of the study cohort

| Age (years) | Gender | Weight (kg) |
|------------|--------|-------------|
| 2          | Female | 11.6        |
| 10         | Male   | 38.1        |
| 15         | Female | 69.1        |
| 13         | Female | 44.5        |
| 15         | Male   | 67.8        |
| 18         | Female | 77.2        |
Anesthesia was provided in three different locations, including the operating room (OR), interventional radiology suite, and radiologic imaging centers. Procedures included surgical interventions; insertion or removal of central venous access devices or feeding tubes; and diagnostic procedures, such as a lumbar puncture or central nervous system (CNS) imaging. The duration of the procedures ranged from 18 to 166 min.

Airway management included a laryngeal mask airway \( (n = 8) \), endotracheal intubation \( (n = 12) \), and native airway with spontaneous ventilation \( (n = 1) \). IV induction with propofol was used in 17 procedures for 5 patients, including 3 patients that required rapid sequence intubation, 1 using succinylcholine and 1 using rocuronium. Inhalation induction with sevoflurane in nitrous oxide \( \left( N_2O \right)/O_2 \) was chosen for two procedures in two patients. A combination of both induction techniques was used for two patients in two procedures. Maintenance anesthesia was accomplished with a volatile agent, predominantly sevoflurane, for 18 of the 21 procedures; propofol infusion was used for one procedure (placement of an NJ feeding tube); and single propofol bolus for two brief procedures (computed tomography [CT] imaging and feeding tube placement). \( N_2O \) was not used for maintenance anesthesia in any of the encounters. Midazolam was administered during three procedures and dexmedetomidine during two. Opioids administered included fentanyl and hydromorphone. The anesthetic agents administered during the procedures are listed in Tables 2 and 3.

There were no documented perioperative respiratory or hemodynamic complications. One patient who had required ICU admission preoperatively had a history of profound bradycardia and cardiac arrest that had previously required resuscitation. After concluding the procedures, the airway device was removed in all, except one patient, and they were transported to the PACU. One patient, who was receiving mechanical ventilation preoperatively, was returned to the pediatric ICU (PICU) with the endotracheal tube (ETT) in place. The PACU stay ranged from 15 to 70 min. Postoperatively, there was no observed deterioration in the clinical status attributable to anesthetic care.

### Discussion

The NMDA receptor is a ligand-gated cation channel that is one of the three types of ionotropic glutamate receptors (iGluRs). Its binds glutamate and glycine; controls the transmembrane movement of cations; and regulates synaptic transmission, synaptic plasticity, and memory function. In anti-NMDA receptor encephalitis, antibodies are formed against the NR1–NR2 heteromers of the NMDA receptor, which bind glycine and glutamate, respectively.\(^{[14]}\) The autoimmune process accelerates the destruction of the NMDA receptor, resulting in a decrease in their surface density, leading to decreased synaptic NMDA receptor-mediated currents and decreased glutamatergic synaptic function.\(^{[15,16]}\) This depressed function leads to memory loss, behavior irregularity, psychosis, arrhythmias, and hypoventilation.

In our retrospective review of anesthetic care at our institution with patients having anti-NMDA receptor encephalitis, sedation or general anesthesia (GA) was provided for 21 procedures for diagnostic or therapeutic procedures. End organ involvement with anti-NMDA receptor encephalitis may include the CNS, cardiac system, and respiratory system. Autonomic nervous system involvement may include dysrhythmias (tachycardia), bradycardia progressing to cardiac arrest, and BP instability (hypotension or hypertension) because of autonomic dysfunction.\(^{[7,8]}\) These episodes have been labeled “paroxysmal sympathetic hyperactivity or PSH”. Although one of our patients manifested abrupt episodes of bradycardia and asystole during the early phase of her disease process within the ICU, no intraoperative problems were noted in our study cohort. However, based on the patient’s clinical status, invasive hemodynamic monitoring may be indicated for patients and treatment with vasoactive agents required.

---

### Table 2: Anesthetic agents used in the study cohort

| Medication                  | Number of patients | Number of procedures |
|----------------------------|--------------------|----------------------|
| Sevoflurane                | 6                  | 12                   |
| Isoflurane                 | 2                  | 3                    |
| Sevoflurane then isoflurane| 1                  | 1                    |
| Desflurane                 | 1                  | 3                    |
| \( N_2O \) (induction)     | 3                  | 4                    |
| Propofol for induction     | 5                  | 19                   |
| Propofol for maintenance   | 1                  | 1                    |
| Fentanyl                   | 5                  | 12                   |
| Hydromorphone              | 2                  | 3                    |
| Midazolam                  | 2                  | 3                    |
| Dexmedetomidine            | 2                  | 2                    |

\( N_2O = \text{Nitrous oxide} \)

### Table 3: Airway devices used in the cohort

| Airway management                  | Number of patients | Number of procedures |
|------------------------------------|--------------------|----------------------|
| Laryngeal mask airway              | 5                  | 8                    |
| ETT                                | 3                  | 12                   |
| Nasal cannula                      | 1                  | 1                    |

ETT = Endotracheal tube
The primary involvement of the CNS is generally the presenting sign and may include the CNS excitability, including behavioral symptoms, abnormal movement, agitation, and seizures. In some patients, it may lead to a diminished response to verbal or tactile stimuli, central hypoventilation, bulbar abnormalities with risk of aspiration, obtundation, and coma requiring intubation and mechanical ventilation, as noted in one of our patients. In selected patients, as was encountered in our study cohort, rapid sequence intubation may be indicated based on the clinical scenario. For these patients, the neuromuscular blocking agent used included either rocuronium or succinylcholine. Alternatively, in patients with limited upper airway involvement, sedation with a native airway or supraglottic device may be appropriate. Anticonvulsant therapy should be optimized preoperatively and medications continued during the perioperative period.\(^\text{[17]}\)

Although uncommon in the pediatric-aged patient, the disorder may be associated with abdominal teratomas, thereby requiring surgical intervention. Given the limited evidence-based medicine available regarding the effect of anesthetic agents on patients with this novel disorder, extrapolation from receptor pharmacology and animal data may be needed. The NMDA receptor and the gamma-aminobutyric acid (GABA) receptors are the two main receptors responsible for the actions of general anesthetic agents.\(^\text{[18]}\) Reversible inhibition of the NMDA receptor by volatile anesthetic agents is concentration-dependent with the half-maximal inhibitory effect produced by isoflurane, sevoflurane, and desflurane at approximately 1.2 minimum alveolar concentration (MAC).\(^\text{[19]}\) Propofol acts primarily on GABA receptors with 10–20% inhibition of NMDA receptors occurring at supraclinical dose.\(^\text{[20,21]}\) Although the majority of anecdotal experience has reported the safe administration of propofol, the inhaled anesthetic agents, neuromuscular blocking agents (vecuronium and rocuronium), and opioids (fentanyl, remifentanil, and hydromorphone), Lapebie \textit{et al} reported worsening of their patient’s neurologic status after GA with sevoflurane and propofol.\(^\text{[22]}\) As this may have been merely a result of the primary disease process, it is not feasible to discern a causal relationship with the anesthetic agents used.

The anesthetic agents, ketamine, xenon, and N2O mediate their anesthetic effects directly through modulating NMDA receptor activity in the hippocampus and basolateral amygdala.\(^\text{[23–27]}\) The predominant antagonism of the NR1 and NR2A-D subtype of the NMDA receptor by these anesthetic agents, especially ketamine, may mimic the primary presenting clinical features of the disorder, including psychosis, hallucinations, and delirium.\(^\text{[27]}\) Given these pharmacologic interactions, theoretical concerns would suggest that these medications should be avoided during anesthetic care to prevent further decline in the NMDA receptor function.

In summary, anti-NMDA receptor encephalitis is an autoimmune disorder resulting from antibodies directed against the NMDA (glutamate) receptor. Antibodies to the NMDA receptor result in multisystem involvement that includes memory loss, behavior irregularity, psychosis, and hypoventilation. Autonomic nervous system involvement may include dysrhythmias, bradycardia progressing to asystole, and BP instability. The volatile anesthetic agents, propofol, dexmedetomidine, and opioids did not result in a further decline in our patients’ status. Anecdotal experience has suggested the potential for an exaggerated effect of propofol on BP resulting in hypotension.\(^\text{[9,13]}\) It has also been suggested that there may be decreased anesthetic requirements related to the effects of the disease process on the NMDA system.\(^\text{[28]}\) Anesthetic care may be further impacted by therapeutic interventions, including the administration of immunosuppressive agents, corticosteroids, and plasmapheresis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005;58:594-604.

2. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, \textit{et al} Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.

3. Matooq AA, Rappoport AS, Yang Y, O’Babatunde J, Bakerywala R, Sheth RD. Anti-NMDA-receptor antibody encephalitis in infants. Epilepsy Behav Case Rep 2015;4:99-101.

4. Titulaer MJ, McCracken L, Gablondo I, Iizuka T, Kawachi I, Bataller L, \textit{et al}. Late-onset anti-NMDA receptor encephalitis. Neurology 2013;81:1058-63.

5. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, \textit{et al}. Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study. Lancet Infect Dis 2010;10:835-44.

6. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.

7. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lat M, \textit{et al}. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.

8. Florance NR, Davis RL, Lam C, Szerka C, Zhou L, Ahmad S, \textit{et al}.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.

9. Splinter WM, Eipe N. Anti-NMDA receptor antibodies encephalitis. Paediatr Anaesth 2009;19:911-3.

10. Senbruna B, Lerman J. Anesthesia management for a boy with anti-N-methyl-D-aspartate receptor encephalitis. A A Case Rep 2015;5:182-4.

11. Simon RW. Anesthetic management and implications of pediatric patients with a diagnosis of anti-N-methyl-D-aspartate receptor encephalitis: Two case reports. AANA J 2014;82:431-6.

12. Khawaja AA, Hakim M, Uffman J, Tobias JD. Anesthetic care for a pediatric patient with anti-N-methyl-D-aspartate receptor encephalitis. J Med Cases 2019;10:151-4.

13. Pryzybikowski PG, Dunkman WJ, Liu R, Chen L. Case report: Anti-N-methyl-D-aspartate receptor encephalitis and its anesthetic implications. Anesth Analg 2011;113:1188-91.

14. Lynch DR, Anegawa NJ, Verdoorn T, Pritchett DB. N-methyl-D-aspartate receptors: Different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Mol Pharmacol 1994;45:540-5.

15. Manto M, Dalmau J, Dideot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: Further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 2010;5:31.

16. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-75.

17. Jones CT, Raman VT, DeVries S, Cole JW, Kelleher KJ, Tobias JD. Optimizing anticonvulsant administration for children before anesthesia: A quality improvement project. J Pediatr Neurol 2014;51:632-40.

18. Chau PL. New insights into the molecular mechanisms of general anaesthetics. Br J Pharmacol 2010;161:288-307.

19. Hollmann MW, Liu HT, Hoenemann CW, Liu WH, Durieux ME. Modulation of NMDA receptor function by ketamine and magnesium. Part II: Interactions with volatile anesthetics. Anesth Analg 2001;92:1182-91.

20. Orser BA, Bertlik M, Wang LY, MacDonald JF. Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurons. Br J Pharmacol 1995;116:1761-8.

21. Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ. Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons. Anesthesiology 2006;104:763-9.

22. Lapèbie FX, Kennel C, Magy L, Projetti F, Honnorat J, Pichon N, et al. Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol 2014;14:5.

23. de Sousa SLM, Dickinson R, Lieb WR, Franks NP. Comparing synaptic actions of the inhalational general anaesthetics isoflurane and xenon. Anesthesiology 2000;106:107-13.

24. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dirkranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1995;4:460-3.

25. Franks NP, Dickinson R, de Sousa SLM, Hall AC, Lieb WR. How does xenon produce anesthesia? Nature 1998;396:324.

26. Ranft A, Kurz J, Becker K, Dodt HU, Ziegglansberger W, Rammes G, et al. Nitrous oxide pre- and postsynaptically attenuates NMDA receptor-mediated neurotransmission in the amygdala. Neuropharmacology 2007;52:716-23.

27. Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: A case series. J Emerg Med 2000;18:447-51.

28. Dilger JP. The effects of general anaesthetics on ligand-gated ion channels. Br J Anaesth 2002;89:1-41.51.